We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Global Market for Contrast Agents Expected to Surge

By MedImaging staff writers
Posted on 20 Mar 2007
Annual growth for medical contrast media is expected to be strong over the next several years, driving the market for everything from x-ray and computed tomography (CT) contrast agents to radiopharmaceuticals used in nuclear medicine, to more than US$15 billion by 2010, according to a medical imaging market report.

With anticipated growth rates ranging from 10-20% for contrast agents used with most modalities, the global market is expected to surge, according to market research firm Kalorama Information (Rockville, MD, USA). Ultrasound contrasting agents, currently making up 13% of the market, are expected to fare extremely well with annual growth rates in the 25-40% range, bringing revenues in this sector from less than $1 billion in 2006 to $4 billion in 2010. At that time, ultrasound contrasting agents will make up more than one-quarter of the market, eating into the current dominance of x-ray agents which make up more than 50% of the current market.

On the cusp of development are highly anticipated contrast agents to aid in the detection of neurologic disorders such as attention-deficit hyperactivity disorder (ADHD); blood pool agents for magnetic resonance angiography (MRA), which is emerging as a viable means of assessing blood vessels; and both diagnostic and therapeutic radiopharmaceuticals, which could have potential for the diagnosis and treatment of Alzheimer's disease.

"Improved contrasting media will be significant in achieving early, cost- and life-saving diagnoses,” noted Joseph Constance, the report's author. "However, developers of new contrast agents and radiopharmaceuticals are faced with regulatory requirements to prove both safety and efficacy of their products, which is particularly important in the development of new agents based on novel chemistries.”


Related Links:
Kalorama Information
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Ultrasound Table
Women’s Ultrasound EA Table
X-Ray Illuminator
X-Ray Viewbox Illuminators
Diagnostic Ultrasound System
DC-80A

Channels

Nuclear Medicine

view channel
Image: LHSCRI scientist Dr. Glenn Bauman stands in front of the PET scanner (Photo courtesy of LHSCRI)

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.